All studies involving MA/MyJ


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. inbred   (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. inbred   (31) both 8-12wks 2010
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. inbred   (89) 2009
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. inbred   (142) m 2014
CGDpheno1 body size and weight Body weight and length. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
Crowley1 behavior observation
with haloperidol
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol
Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol
Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. inbred w/CC8   (27) m 9-28wks 2012
Finn1 bottle choice test
with ethanol
Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). inbred   (22) both 8-12wks 2007
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans
Susceptibility to infection with Candida albicans. inbred   (36) f 8-12wks 2011
Hadsell1 body weight Daily body weight gain of cross-fostered pups. inbred   (31) f 14-18wks 2012
Hadsell1 colony observation Maternal nurturing study. inbred   (31) f 14-18wks 2012
Hadsell2 mineral quantification concentrations of various minerals in milk inbred   (31) f 14-20wks 2018
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289
DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. inbred   (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. inbred w/CC7   (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. inbred w/CC7   (41) both 6-7wks 2008
HMDPpheno1 DXA Bone mineral density (whole body, femur, spine). HMDP   (96) m 16wks 2011
HMDPpheno10 metabolite quantification Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. HMDP   (99) m 16wks 2010
HMDPpheno2 NMR Percent fat. HMDP   (99) m 16wks 2010
HMDPpheno3 tail cuff Heart rate and blood pressure. Conscious mice. HMDP   (58) m 9-10wks 2012
HMDPpheno4 fear conditioning test Contextual fear, cued fear. HMDP   (94) m 10wks 2011
HMDPpheno5 complete blood count Hematology. HMDP   (83) m 16wks 2013
HMDPpheno6 metabolite quantification Liver metabolic profiling. Molecular measures of amino acids. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno7 metabolite quantification Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno8 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno9 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. HMDP   (106) m 16wks 2014
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. inbred   (56) both 2000
Jax4 colony observation Appearance, coat color inbred   (61) both 2006
Johnson1 ABR test Auditory brainstem response. inbred   (51) both 3-12wks and 15-72wks 2000
Kumar2 open field test Distance traveled, after first 10 min and after 55 min. other   (58) both 7-26wks 2019
Kumar3 body weight Body weight inbred w/CC8   (62) both 8-14wks 2021
Kumar3 open field test Locomotor activity and grooming behavior. inbred w/CC8   (62) both 8-14wks 2021
Massett1 body weight Body weight inbred   (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. inbred   (34) both 8wks 2012
Naggert1 body weight
with high-fat diet
High-fat diet for 8wks. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Paigen2 histopathology
with high-fat diet
Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Peters1 complete blood count Hematology. inbred w/CC7   (43) both 10wks 2001
Pletcher1 body weight Body weight inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 10 min test. inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. inbred   (32) m 7-9wks 2007
Tarantino1 body weight
with cocaine
Body weight inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. inbred   (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. inbred   (37) f 8-10wks 2016
Tarantino2 open field test
with ovariectomy
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. inbred   (37) f 8-10wks 2016
Threadgill1 biomarker quantification
with acetaminophen
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolic panel
with acetaminophen
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen
Liver weight after acetaminophen (several doses) vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Tordoff3 body weight Body weight inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. inbred w/CC7   (40) both 9-15wks 2002
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X HMDP   (248) both 2018
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC7   (40) both 5-6wks 2002
Willott1 body weight Body weight inbred w/CC7   (40) both 5-6wks 2002
Wiltshire1 elevated plus maze Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Zheng1 tympanometry Middle ear function. inbred   (61) both 15-51d 2008
Zimmermann1 body weight Body weight inbred   (30) both 7-15 wks 2020
Zimmermann1 intake monitoring Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020
Zimmermann1 monitoring system Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020